propylthiouracil and estradiol-benzoate--progesterone-drug-combination

The separate and combined effects of Synovex-S (SYN) ear implants and thyroxine (T4)-5'-monodeiodinase inhibition (Trial 1) and T3 injection to create a mild elevation in circulating T3 concentrations (Trial 2) on BW gain and composition of gain were studied. Trial 1 used 24, 285-kg Angus steers in two experimental phases. Low-level feeding of propylthiouracil (PTU, 1.5 mg/kg BW daily) was used to achieve inhibition of T4-5'-monodeiodinase activity (TMA). Twelve steers received neither treatment (control) and 12 received SYN+PTU (hypothesized to maximize weight gain) from 0 to 56 d (phase 1) in a single factor treatment comparison. Subsequently, PTU was fed to six control steers and not fed to six of the original SYN+PTU steers from 56 to 175 d (phase 2) in a 2 x 2 arrangement of treatments. Trial 2 used 24, 302-kg Angus-Hereford steers. Treatments were without or with SYN and without or with sc injections of T3 in polyethylene glycol (2 micrograms/kg BW every 48 hr) in a 2 x 2 factorial arrangement of treatments. In both trials, all steers were individually fed a diet of a corn-based concentrate and silage mixture at an equal metabolizable energy intakes per unit of metabolic body weight (.25 Mcal/kg BW.75). Measurements of daily dry matter intakes, weekly BW, 28-d estimates of empty body components (measured by urea dilution), final TMA (trial 1) and plasma thyroid hormone concentrations were obtained. In both trials, SYN increased BW gain and protein accretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Animals; Body Composition; Cattle; Drug Combinations; Drug Implants; Estradiol; Male; Progesterone; Propylthiouracil; Thyroid Gland; Triiodothyronine; Weight Gain

Three studies assessed the effect of thyroid status on regulation of plasma IGF-I in cattle. First, four Angus-Hereford steers (av wt 345 kg) were fed 4 mg/d propylthiouracil daily for 35 d. With continued feeding of PTU steers were sequentially injected with thyroxine (T4, 5 mg/d, IM for 5 d) followed by triiodothyronine (T3, 2 mg/d, IM for 5 d). An injection of bovine pituitary growth hormone (GH, 0.1 mg/kg, IM) was given to each steer on day 35 of PTU, day 5 of T4 and again on day 5 of T3. PTU alone increased plasma thyroid stimulating hormone (TSH), decreased plasma T4 and T3 but had no influence on IGF-I. T3, but not T4, lowered plasma TSH, IGF-I and the IGF-I response to GH (P < .05). Next, twelve bull calves (av wht 167 kg) were divided equally into two groups. A control group was injected daily for five d with buffered saline; the experimental group was concurrently treated with T3 (5 mg/d, sc) for five d. Beginning the sixth day, all calves were injected with GH (0.1 mg/kg, IM daily) for three d with the respective buffer or T3 treatments continuing. Plasma IGF-I was depressed 29% by T3. The incremental area under the three-d response curve was less (P < .03) in T3 cattle. A growth trial was conducted in which twenty-four Angus x Hereford steers were injected daily with T3 (2 mg/kg, bi-daily x 56 d) or implanted with Synovex-S (S) in a 2 x 2 factorial arrangement. Synovex increased empty body protein gain (EBPG) and plasma IGF-I 15.5 and 27.9% (P < .01), respectively; T3 decreased EBPG and plasma IGF-I 13.9 and 15.1% (P < .07), respectively, in steers which maintained suppression in plasma TSH. The data support the conclusion that elevated T3 decreases plasma IGF-I, in part, through a diminished GH-responsiveness and anabolic treatments such as S can reverse the effects of excess T3.

Topics: Animals; Cattle; Cattle Diseases; Drug Combinations; Drug Interactions; Estradiol; Gene Expression Regulation; Growth Hormone; Hypothyroidism; Insulin-Like Growth Factor I; Least-Squares Analysis; Male; Multivariate Analysis; Pituitary Gland; Progesterone; Propylthiouracil; Protein Biosynthesis; Random Allocation; Thyroid Gland; Thyrotropin; Thyroxine; Time Factors; Triiodothyronine

The effects of propylthiouracil (PTU)-induced thyroid hormone imbalance on GH, TSH and IGF-I status in cattle were examined. In the first study, four crossbred steers (avg wt 350 kg) were fed a diet dressed with PTU (0, 1, 2 or 4 mg/kg/d BW) in a Latin square design with four 35-d periods. On day 29 in each period, steers were challenged with an intrajugular bolus of thyrotropin releasing hormone (TRH, 1.0 microgram/kg). Blood samples were obtained to assess the change in plasma GH and TSH as affected by PTU. Plasma IGF-I was measured from blood samples obtained before and after (every 6 hr for 24 hr) intramuscular injection of bovine GH (0.1 mg/kg, day 31). Doses of 1 and 2 mg/kg PTU increased plasma T4 (P < .01). At 4 mg/kg, PTU depressed T4 concentrations to 30% of control (P < .01). Plasma T3 linearly decreased with increasing doses of PTU (P < .01). Plasma TSH increased when PTU was fed at 4 mg/kg (P < .05) while the TSH response to TRH declined with increasing PTU (P < .02). Neither basal nor TRH-stimulated plasma concentration of GH was affected by PTU; the IGF-I response to GH tended to increase at the 1 and 2 mg/kg PTU (P < .01). In a second study 24 crossbred steers were fed PTU (1.5 mg/kg) for 119 d in a 2 x 2 factorial design with implantation of the steroid growth effector, Synovex-S (200 mg progesterone + 20 mg estradiol), as the other main effect. Basal plasma GH and IGF-I were not affected by PTU treatment. Synovex increased plasma concentration (P < .01) of IGF-I without an effect on plasma GH. The data suggest that mild changes in thyroid status associated with PTU affects regulation of T3, T4 and TSH more than GH or IGF-I in steers.

Topics: Animals; Cattle; Cattle Diseases; Drug Combinations; Estradiol; Growth Hormone; Hypothyroidism; Insulin-Like Growth Factor I; Male; Progesterone; Propylthiouracil; Thyroid Hormones; Thyrotropin; Thyrotropin-Releasing Hormone